Clinical Trial Update: Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing two first-line regimens (carboplatin-paclitaxel or oxaliplatin-capecitabine) with or without bevacizumab. The study includes newly dia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Borderline Ovarian Tumor
• Fallopian Tube Cancer
• Ovarian Cancer
• Ovarian Mucinous Cystadenocarcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Capecitabine (capecitabine)
• OXALIPLATIN (Oxaliplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-03-18